Page last updated: 2024-12-06

febarbamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Febarbamate is a GABAergic anticonvulsant that was initially synthesized as a barbiturate analog. It acts by enhancing the inhibitory effects of GABA in the central nervous system. Febarbamate has been studied for its potential efficacy in treating various neurological conditions, including epilepsy, anxiety, and muscle spasms. The mechanism of action of Febarbamate involves binding to GABA receptors and increasing the frequency of chloride ion channel opening, leading to hyperpolarization of neurons. Febarbamate has demonstrated significant anticonvulsant activity in both preclinical and clinical studies, and it has been used in the treatment of generalized tonic-clonic seizures and partial seizures. However, due to its sedative side effects and potential for drug interactions, its use has declined in recent years. Febarbamate continues to be studied for its potential in treating specific types of epilepsy, particularly in cases where other medications have failed. Research is ongoing to explore its potential therapeutic benefits and to understand its mechanisms of action in more detail.'

febarbamate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25803
CHEMBL ID2104283
CHEBI ID135655
SCHEMBL ID18473
MeSH IDM0044032

Synonyms (39)

Synonym
D07275
13246-02-1
febarbamate (inn)
febarbamatum [inn-latin]
tymium
einecs 236-226-3
g-tril
1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid carbamate ester
carbamic acid, ester with 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid
3-(3-butoxy-3-carbamoyloxypropyl)-5-ethyl-5-phenylbarbituric acid
1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenylbarbituric acid, carbamate ester
3-(gamma-butoxy-beta-carbamyl-beta-propanol)-5-phenyl-5-ethylmalonylurea
febarbamate
febarbamate [inn:dcf]
go 560
brn 0591584
barbituric acid, 1-(3-butoxy-2-hydroxypropyl)-5-ethyl-5-phenyl-, carbamate (ester)
phebarbamate
phenobamate
febarbamato [inn-spanish]
getril
CHEBI:135655
[1-butoxy-3-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)propan-2-yl] carbamate
febarbamatum
5z48onn38p ,
go-560
unii-5z48onn38p
febarbamato
5-24-09-00304 (beilstein handbook reference)
febarbamate [who-dd]
febarbamate [mi]
febarbamate [inn]
febarbamate [mart.]
CHEMBL2104283
SCHEMBL18473
Q5439707
DB13303
1-butoxy-3-(5-ethyl-2,4,6-trioxo-5-phenyl-1,3-diazinan-1-yl)propan-2-yl carbamate
DTXSID40864380

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (12.50%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]